Is genetic screening better at prediction of disease than the current traditional phenotypic methods? Do we have enough expertise to move genetic diagnosis into the clinic? Is direct-to-consumer genetics dangerous? Find out what leading dementia researchers think about the trends in the field and what are their recommendations for the future. Panelists in the session: -Dr. Jonathan Rohrer, University College London -Prof. Julie Williams, UKDRI, University of Cardiff -Prof. Anne Bassett, University of Toronto Session moderated by: Prof. John Hardy, UKDRI, University College London For other videos and dementia research-related resources, visit http://ion.illumina.com/genetics-of-dementia-resource-library-yt For Research Use Only. Not for use in diagnostic procedures QB #6255 Subscribe to the Illumina video channel http://www.youtube.com/subscription_center?add_user=IlluminaInc A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world’s sequencing data.* Through collaborative innovation, Illumina is fueling groundbreaking advancements in oncology, reproductive health, genetic disease, microbiology, agriculture, forensic science, and beyond. *Data calculations on file. Illumina, Inc., 2015. View customer spotlight videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajfheLzgbI4S7xBn7IDbt79 View Illumina webinars https://www.youtube.com/playlist?list=PLKRu7cmBQlahpXlnrrXlQw9itVJ8yHwUZ View Illumina product videos https://www.youtube.com/playlist?list=PLKRu7cmBQlaj6YuZmkfxZcT9twqDgP2Xd View Illumina support videos https://www.youtube.com/playlist?list=PLKRu7cmBQlajbm2KGsICWb-JOnusJfYvM